Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
Holding RCEL?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.39Last Year’s EPS
-0.28Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 10, 2020
|% Change Since: -30.24%
|Next Earnings Date:Jul 09, 2020
Earnings Call Sentiment|Neutral
The earnings call highlighted strong commercial revenue growth, successful product transitions, and a positive outlook with new product launches and international expansion plans. However, it also noted increased operating expenses, a significant net loss, and delays in international approvals. Despite these challenges, the company maintains a positive growth trajectory.Company Guidance
During the Q3 2024 earnings call for AVITA Medical, the company provided optimistic guidance driven by a 29% increase in commercial revenue, reaching $19.5 million. This growth was largely attributed to the accelerated transition to the RECELL GO platform, which accounted for approximately 75% of the revenue base by the end of September. The company reported a year-over-year increase in revenue of 44% and projected Q4 revenue between $22.3 million to $24.3 million, representing 58% to 72% growth compared to Q4 2023. AVITA Medical also highlighted the upcoming launches of Cohealyx and RECELL GO Mini, expected to further boost revenue. The gross profit margin for the quarter was 83.7%, with expectations for a range of 85% to 86% for the full year. The company's strategic initiatives aim for cash flow breakeven and GAAP profitability by Q3 2025, without significant organizational expansion.Record Commercial Revenue Growth
Achieved $19.5 million in commercial revenue for Q3 2024, a 29% increase over the previous quarter and a 44% year-over-year growth.
Successful Transition to RECELL GO
Successfully transitioned approximately 75% of the revenue base to the RECELL GO platform within four months of FDA approval.
Expansion of Account Base
Now have approximately 300 accounts across burns and trauma centers for full-thickness skin defects, more than double the number of accounts from a year ago.
Gross Profit Margin Stability
Gross profit margin for the quarter was 83.7%, with expectations to maintain a range of 85% to 86% for the full year 2024.
Positive Future Revenue Guidance
Guided Q4 2024 commercial revenue to be in the range of $22.3 million to $24.3 million, indicating sequential growth of 14% to 25%.
New Product Launches and International Expansion
Plans to launch Cohealyx and RECELL GO Mini in early 2025 and expand into Europe and Australia.
---
RCEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RCEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $12.40 | $11.95 | -3.63% |
| Aug 08, 2024 | $7.93 | $9.57 | +20.68% |
| May 13, 2024 | $8.35 | $8.72 | +4.43% |
| Feb 22, 2024 | $17.01 | $17.10 | +0.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Avita Medical (RCEL) report earnings?
Avita Medical (RCEL) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Avita Medical (RCEL) earnings time?
Avita Medical (RCEL) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RCEL EPS forecast?
RCEL EPS forecast for the fiscal quarter 2024 (Q4) is -0.39.
---